Do ESR1-related mutations generate neoantigens in hormone-receptor-positive HER2-negative metastatic breast cancer?

被引：0
|
作者：
Lopez, M. [1 ]
Spehner, L. [1 ]
Ramseyer, M. [2 ]
Bouard, A. [2 ]
Dobi, E. [1 ]
Curtit, E. [1 ]
Borg, C. [1 ]
Mansi, L. [1 ]
机构：
[1] Hop Jean Minjoz, CHRU Besancon, Team Therapeut Immunomol Canc, Besancon, France
[2] Doubs, UMR1098, Besancon, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.653
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477P
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [1] Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
    Joseph Gligorov
    Jean-Pierre Lotz
    Breast Cancer Research and Treatment, 2008, 112 : 53 - 66
  • [2] Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
    Gligorov, Joseph
    Lotz, Jean-Pierre
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (Suppl 1) : 53 - 66
  • [3] The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Grinshpun, Albert
    Sandusky, Zachary M.
    Jeselsohn, Rinath
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 169 - 181
  • [4] Is the overall survival after hormone therapy for hormone-receptor-positive, HER2-negative metastatic breast cancer still better than for triple-negative metastatic breast cancer?
    Watanabe, J.
    Hayashi, T.
    Tadokoro, Y.
    Nishimura, S.
    Takahashi, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [6] ASSESSMENT OF EARLY PROGRESSION RISK FOR PATIENT WITH ESR1 MUTATIONS AND HORMONE RECEPTOR POSITIVE (HR+)/ HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Tarasenko, Tetiana
    Syvak, Liubov
    Martyniuk, Olena
    Bondar, Maryna
    BREAST, 2023, 71 : S52 - S53
  • [7] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
    Lankford, M. L.
    Britton, S. L.
    Buettner, A. D.
    Scharf, M.
    Tiscione, B.
    Willey, J. P.
    Mahtani, R. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [8] Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer
    Ferro, Antonella
    Campora, Michela
    Caldara, Alessia
    De Lisi, Delia
    Lorenzi, Martina
    Monteverdi, Sara
    Mihai, Raluca
    Bisio, Alessandra
    Dipasquale, Mariachiara
    Caffo, Orazio
    Ciribilli, Yari
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (12)
  • [9] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [10] Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
    Luboff, Alexa J.
    DeRemer, David L.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (12) : 1229 - 1237
12345